GuideLicensing

How to license a technology from NIH: the technology transfer process

NIH technology transfer for licensees: the five-step licensing process, licence types, the application and development plan, US manufacturing and costs.

By Dr. Abhay Tharmatt, Research Scientist, R&D, Zernyx Innovations 7 min read
Short answer

The US National Institutes of Health licenses inventions from its laboratories through a five-step process: find the technology, contact the named Licensing and Patenting Manager, submit the NIH Application for License with a development plan, negotiate from NIH's model agreement, then sign. Under 35 U.S.C. 209, an exclusive licence needs at least 15 days' public notice first.

The National Institutes of Health runs a large intramural research programme, and the US government owns the inventions its scientists make. Those inventions, from diagnostic reagents to vaccine components and research tools, are licensed to companies through NIH's technology transfer offices.

For an Indian biotech, pharma or diagnostics company, NIH can be a source of well-characterised technologies with published science behind them. The process is formal and the law sets some conditions you cannot negotiate away. This guide covers how NIH licensing works, the licence types, what the application asks for, the federal rules that shape the deal and what it may cost.

How does NIH license its technologies?

NIH describes a five-step licensing process:

  1. Identify technologies by searching the technology abstracts on NIH's technology transfer site.
  2. Contact the Licensing and Patenting Manager named at the end of the abstract.
  3. Complete and submit the NIH Application for License to that manager.
  4. Review the model agreement and negotiate terms. The manager usually prepares the first draft.
  5. Receive the signed licence. A Royalties Coordinator sends a welcome package with an invoice, and tangible materials ship once payment is confirmed.

NIH's licensing overview notes that hundreds of new inventions are made each year at NIH and CDC laboratories, and that nine NIH institutes or centres transfer inventions through licences. In practice, you deal with the office that manages the technology you want.

Licensing a technology from NIH

1
Find the abstractNIH technology transfer site
2
Contact the named managerLicensing and Patenting Manager
3
Submit the applicationDevelopment plan, terms, market
4
Negotiate from the modelManager drafts first
5
Sign and payMaterials ship after payment

Which licence types does NIH offer?

Licence type What it allows When it suits you
Commercial evaluation Non-exclusive right to make and use the technology to assess its commercial potential, for a limited number of months You want to test before committing
Internal commercial use Non-exclusive right to use the invention internally as a development tool, without selling it Research tools and reagents for your own R&D
Non-exclusive patent Commercialise a patented invention, alongside other licensees Platform technologies, or markets where exclusivity is not needed
Exclusive patent Commercialise a patented invention as the only licensee in the agreed scope Products that need years of investment, such as therapeutics
Biological materials Make, use or sell biological materials not protected by patents, typically non-exclusive Cell lines, antibodies and other materials

NIH's licensing FAQs add that licences are usually worldwide but can be granted by country or region. For an Indian company focused on India and nearby markets, a territory-limited licence can be cheaper and faster.

What does the application ask for?

The NIH Application for License (model 9-2025) is longer than a typical university form. Its main sections:

Section What to prepare
Basic information about the applicant Contacts, corporate status, small business and start-up status, a tax identification number before signing
Type of licence sought Exclusive, co-exclusive, non-exclusive, evaluation, start-up, or biological materials
Description of the applicant Financial resources and manufacturing capability, including a statement on US manufacture
Proposed licence terms Your suggested financial terms
Development plan R&D and marketing plan with staged timelines, money and people needed; an access plan for certain drugs, biologics and devices
Market analysis Sales projections

The development plan carries the most weight. Federal law, 35 U.S.C. 209(f), says no licence on a patent or application can be granted without a development or marketing plan, and NIH's FAQs say the plan is the basis for performance benchmarks written into the licence. A vague plan produces either a slow negotiation or benchmarks you cannot meet.

Which federal rules shape the licence?

Because NIH inventions are federally owned, 35 U.S.C. 209 applies directly:

Rule Subsection What it means for an Indian licensee
Exclusive licence conditions 209(a) Exclusivity must be a reasonable and necessary incentive, serve the public and not substantially lessen competition
US manufacturing 209(b) Licences to use or sell in the US normally go to licensees who agree products will be made substantially in the US
Small business preference 209(c) Small businesses get first preference for exclusive licences if equally likely to commercialise
Government licence and reports 209(d) The government keeps a non-transferable, irrevocable, paid-up licence worldwide; licensees file periodic utilisation reports
Termination 209(d) The licence can be terminated for failing the practical application commitment or breaching the manufacturing rule
Public notice 209(e) At least 15 days' notice before an exclusive or partially exclusive licence, with comments considered
Development plan 209(f) Required before any patent licence

The manufacturing rule bites only on rights to use or sell in the United States. An Indian company licensing NIH technology for India alone is outside it, though the other conditions still apply. Our guide to licensing from a US university explains the similar Bayh-Dole rules for university inventions, and US vs Indian patent license clauses covers the contract points that change across borders.

What does an NIH licence cost?

NIH does not publish a standard fee list, and its FAQs say royalties depend on the type of licence. Its start-up programme gives a rare public reference point. NIH says its start-up exclusive licences were offered to companies less than five years old, with less than $5 million raised and fewer than 50 employees. They carried a 1.5% earned royalty, a 15% royalty on sublicensing income and deferred execution and minimum royalties. A one-year exclusive evaluation option carried a $2,000 execution fee. NIH now says each institute decides case by case whether to use the start-up licence.

Expect, in a standard exclusive licence, some mix of an execution royalty, a minimum annual royalty, an earned royalty on sales, reimbursement of patent costs and milestone payments.

Illustration with invented figures, at an assumed exchange rate of ₹85 to the US dollar. A Hyderabad diagnostics company takes a non-exclusive licence for India and South Asia on an NIH antigen patent.

Item US dollars Rupees
Execution royalty $15,000 ₹12,75,000
Minimum annual royalty $5,000 ₹4,25,000
Earned royalty on $1,200,000 of net sales at 3% $36,000 ₹30,60,000
Share of past patent costs $10,000 ₹8,50,000

The minimum annual royalty is credited against the earned royalty here, so year one costs ₹51.85 lakh: the execution royalty, the earned royalty and the patent cost share.

Year one payments to NIH in this illustration

₹51.85 lakh in year one
59%25%16%
Earned royalty3% of net sales59%
Execution royaltyPaid once at signing25%
Patent costsShare of past costs16%
Invented figures for illustration only.

The company also deducts Indian TDS on royalty paid to a non-resident. Take advice on the applicable section, rate and treaty relief.

Common mistakes

  • Sending a thin development plan. It sets the benchmarks you will be held to.
  • Asking for exclusive worldwide rights when you plan to sell only in Asia. It raises costs and brings the US manufacturing rule into play.
  • Forgetting the 15-day public notice when planning a launch date for an exclusive deal.
  • Assuming a US patent covers India. Check whether NIH filed in India; if not, you may be paying for rights you do not need here. Patent due diligence lists the checks.
  • Ignoring royalty stacking when several NIH and university patents cover one product; see royalty stacking.

My view: NIH is worth approaching for research tools and well-characterised biological materials, where non-exclusive licences are common and the process is predictable. I cannot say how long a typical NIH negotiation takes for an Indian applicant, because NIH does not publish timelines; ask the manager at the first call.

To compare an NIH technology with other options before you apply, Zernyx Hub has mapped patents from universities across India, with AI business insight on each.

Common questions

Can an Indian company license a technology from NIH?

NIH's pages do not bar foreign companies, and licences can be granted worldwide or by country or region. Federal law gives first preference for exclusive licences to small businesses and expects products sold in the US to be made substantially in the US, so plan how you will handle the US market.

What licence types does NIH offer?

NIH lists five: a commercial evaluation licence, an internal commercial use licence, a non-exclusive patent licence, an exclusive patent licence, and a biological materials licence for materials not protected by patents.

Does NIH publish a notice before granting an exclusive licence?

Yes. Under 35 U.S.C. 209(e), an exclusive or partially exclusive licence cannot be granted until public notice has been given at least 15 days in advance and comments have been considered. NIH's licensing FAQs say comments generally must arrive within 15 days of publication.

What does the NIH licence application ask for?

The 2025 NIH Application for License asks for applicant details, the type of licence sought, proposed financial terms, a description of the applicant including manufacturing capability, a development plan with timelines, and a market analysis with sales projections. It lists no application fee.

Dr. Abhay Tharmatt
About the author

Dr. Abhay Tharmatt

Research Scientist, R&D, Zernyx Innovations

Connect on LinkedIn
More about Dr. Abhay Tharmatt
  • Ph.D. in Pharmaceutical Sciences, BITS Pilani.

Find a technology you can own.

Search patented technologies from Indian universities and labs, check their readiness and license the right one on Zernyx Hub.

Explore Zernyx Hub

Keep reading

Looking for something else?